Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management

Research output: Contribution to journalReviewpeer-review

Harvard

Cheung, CMG, Arnold, JJ, Holz, FG, Park, KH, Lai, TYY, Larsen, M, Mitchell, P, Ohno-Matsui, K, Chen, S-J, Wolf, S & Wong, TY 2017, 'Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management', Ophthalmology, vol. 124, no. 11, pp. 1690-1711. https://doi.org/10.1016/j.ophtha.2017.04.028

APA

Cheung, C. M. G., Arnold, J. J., Holz, F. G., Park, K. H., Lai, T. Y. Y., Larsen, M., Mitchell, P., Ohno-Matsui, K., Chen, S-J., Wolf, S., & Wong, T. Y. (2017). Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. Ophthalmology, 124(11), 1690-1711. https://doi.org/10.1016/j.ophtha.2017.04.028

CBE

Cheung CMG, Arnold JJ, Holz FG, Park KH, Lai TYY, Larsen M, Mitchell P, Ohno-Matsui K, Chen S-J, Wolf S, Wong TY. 2017. Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. Ophthalmology. 124(11):1690-1711. https://doi.org/10.1016/j.ophtha.2017.04.028

MLA

Vancouver

Author

Cheung, Chui Ming Gemmy ; Arnold, Jennifer J ; Holz, Frank G ; Park, Kyu Hyung ; Lai, Timothy Y Y ; Larsen, Michael ; Mitchell, Paul ; Ohno-Matsui, Kyoko ; Chen, Shih-Jen ; Wolf, Sebastian ; Wong, Tien Yin. / Myopic Choroidal Neovascularization : Review, Guidance, and Consensus Statement on Management. In: Ophthalmology. 2017 ; Vol. 124, No. 11. pp. 1690-1711.

Bibtex

@article{93641a15c79147e991d1d9a4a014e152,
title = "Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management",
abstract = "TOPIC: The aim of this article is to review and compile available information on the classification, pathophysiology, and clinical features of myopic choroidal neovascularization (CNV); to describe the latest data on the management of this disease; and to present guidance.CLINICAL RELEVANCE: In the United States, myopia affects approximately 34 million people (2010), and similar figures have been reported in Europe. Pathologic myopia (PM), a possible consequence of myopia, is estimated to affect up to 3% of the global population. One of the most serious complications of PM is myopic CNV, which often leads to a sudden onset but progressive decline in central vision and is associated with a poor prognosis unless treated. Furthermore, 35% of patients with myopic CNV develop bilateral disease in the fellow eye within 8 years. Although intravitreal anti-vascular endothelial growth factor (VEGF) therapies have had a major impact on the management of patients with myopic CNV, there remain significant gaps in our understanding of this condition and how to best administer treatment. Additionally, the long-term safety and efficacy of these treatments are largely unknown.METHODS: We carried out a literature review (September 2015) of all English-language articles in PubMed resulting from searches of the following terms: {"}choroidal neovascularization{"} AND {"}myopia{"} OR {"}myopic macular degeneration{"} OR {"}degenerative myopia{"} OR {"}myopic maculopathy{"} OR {"}myopic retinopathy{"} OR {"}pathological myopia{"} OR {"}pathologic myopia.{"}RESULTS: We screened a total of 566 abstracts, and 250 articles were deemed relevant for full publication review. We excluded a further 71, but an additional 44 articles were identified. This resulted in 223 articles being used to develop this review.CONCLUSIONS: Highly myopic patients experiencing a sudden loss of central vision should be referred for further examination. Once a diagnosis of myopic CNV has been confirmed, after fluorescein angiography, treatment initiation should be prompt and anti-VEGF agents considered as first-line therapy, unless contraindicated. Continued monitoring of patients is required to assess any progression or recurrence of the condition.",
keywords = "Angiogenesis Inhibitors, Choroidal Neovascularization, Consensus, Databases, Factual, Disease Progression, Fluorescein Angiography, Humans, Myopia, Degenerative, Practice Guidelines as Topic, Visual Acuity, Journal Article, Review",
author = "Cheung, {Chui Ming Gemmy} and Arnold, {Jennifer J} and Holz, {Frank G} and Park, {Kyu Hyung} and Lai, {Timothy Y Y} and Michael Larsen and Paul Mitchell and Kyoko Ohno-Matsui and Shih-Jen Chen and Sebastian Wolf and Wong, {Tien Yin}",
note = "Copyright {\textcopyright} 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.",
year = "2017",
doi = "10.1016/j.ophtha.2017.04.028",
language = "English",
volume = "124",
pages = "1690--1711",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc",
number = "11",

}

RIS

TY - JOUR

T1 - Myopic Choroidal Neovascularization

T2 - Review, Guidance, and Consensus Statement on Management

AU - Cheung, Chui Ming Gemmy

AU - Arnold, Jennifer J

AU - Holz, Frank G

AU - Park, Kyu Hyung

AU - Lai, Timothy Y Y

AU - Larsen, Michael

AU - Mitchell, Paul

AU - Ohno-Matsui, Kyoko

AU - Chen, Shih-Jen

AU - Wolf, Sebastian

AU - Wong, Tien Yin

N1 - Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

PY - 2017

Y1 - 2017

N2 - TOPIC: The aim of this article is to review and compile available information on the classification, pathophysiology, and clinical features of myopic choroidal neovascularization (CNV); to describe the latest data on the management of this disease; and to present guidance.CLINICAL RELEVANCE: In the United States, myopia affects approximately 34 million people (2010), and similar figures have been reported in Europe. Pathologic myopia (PM), a possible consequence of myopia, is estimated to affect up to 3% of the global population. One of the most serious complications of PM is myopic CNV, which often leads to a sudden onset but progressive decline in central vision and is associated with a poor prognosis unless treated. Furthermore, 35% of patients with myopic CNV develop bilateral disease in the fellow eye within 8 years. Although intravitreal anti-vascular endothelial growth factor (VEGF) therapies have had a major impact on the management of patients with myopic CNV, there remain significant gaps in our understanding of this condition and how to best administer treatment. Additionally, the long-term safety and efficacy of these treatments are largely unknown.METHODS: We carried out a literature review (September 2015) of all English-language articles in PubMed resulting from searches of the following terms: "choroidal neovascularization" AND "myopia" OR "myopic macular degeneration" OR "degenerative myopia" OR "myopic maculopathy" OR "myopic retinopathy" OR "pathological myopia" OR "pathologic myopia."RESULTS: We screened a total of 566 abstracts, and 250 articles were deemed relevant for full publication review. We excluded a further 71, but an additional 44 articles were identified. This resulted in 223 articles being used to develop this review.CONCLUSIONS: Highly myopic patients experiencing a sudden loss of central vision should be referred for further examination. Once a diagnosis of myopic CNV has been confirmed, after fluorescein angiography, treatment initiation should be prompt and anti-VEGF agents considered as first-line therapy, unless contraindicated. Continued monitoring of patients is required to assess any progression or recurrence of the condition.

AB - TOPIC: The aim of this article is to review and compile available information on the classification, pathophysiology, and clinical features of myopic choroidal neovascularization (CNV); to describe the latest data on the management of this disease; and to present guidance.CLINICAL RELEVANCE: In the United States, myopia affects approximately 34 million people (2010), and similar figures have been reported in Europe. Pathologic myopia (PM), a possible consequence of myopia, is estimated to affect up to 3% of the global population. One of the most serious complications of PM is myopic CNV, which often leads to a sudden onset but progressive decline in central vision and is associated with a poor prognosis unless treated. Furthermore, 35% of patients with myopic CNV develop bilateral disease in the fellow eye within 8 years. Although intravitreal anti-vascular endothelial growth factor (VEGF) therapies have had a major impact on the management of patients with myopic CNV, there remain significant gaps in our understanding of this condition and how to best administer treatment. Additionally, the long-term safety and efficacy of these treatments are largely unknown.METHODS: We carried out a literature review (September 2015) of all English-language articles in PubMed resulting from searches of the following terms: "choroidal neovascularization" AND "myopia" OR "myopic macular degeneration" OR "degenerative myopia" OR "myopic maculopathy" OR "myopic retinopathy" OR "pathological myopia" OR "pathologic myopia."RESULTS: We screened a total of 566 abstracts, and 250 articles were deemed relevant for full publication review. We excluded a further 71, but an additional 44 articles were identified. This resulted in 223 articles being used to develop this review.CONCLUSIONS: Highly myopic patients experiencing a sudden loss of central vision should be referred for further examination. Once a diagnosis of myopic CNV has been confirmed, after fluorescein angiography, treatment initiation should be prompt and anti-VEGF agents considered as first-line therapy, unless contraindicated. Continued monitoring of patients is required to assess any progression or recurrence of the condition.

KW - Angiogenesis Inhibitors

KW - Choroidal Neovascularization

KW - Consensus

KW - Databases, Factual

KW - Disease Progression

KW - Fluorescein Angiography

KW - Humans

KW - Myopia, Degenerative

KW - Practice Guidelines as Topic

KW - Visual Acuity

KW - Journal Article

KW - Review

U2 - 10.1016/j.ophtha.2017.04.028

DO - 10.1016/j.ophtha.2017.04.028

M3 - Review

C2 - 28655539

VL - 124

SP - 1690

EP - 1711

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 11

ER -

ID: 52800230